In early prostate cancer, which is the most common type of prostate cancer, actually we re-stratify the patient to low, intermediate and high risk based on clinical pathologic factors like the PSA, Gleason, percentage of course, and clinical T-stage. And this model, for example, the NCCN model, can either underestimate aggressive tumors or overestimate indolent cancers...
In early prostate cancer, which is the most common type of prostate cancer, actually we re-stratify the patient to low, intermediate and high risk based on clinical pathologic factors like the PSA, Gleason, percentage of course, and clinical T-stage. And this model, for example, the NCCN model, can either underestimate aggressive tumors or overestimate indolent cancers. And this can lead to overtreatment or undertreatment. And then we often need better re-stratification tools like the Decipher. And that’s what we analyze in the present study. So most of the data about the Decipher genomic classifier come from American patients and there is limited data from non-American patients so number one we wanted to see how the Decipher performs in early prostate cancer in a large cohort of about 1,200 patients that are non-American and we saw actually a significant NCCN risk reclassification with the Decipher either to a low risk or to a high risk. That was the first aim. And then the second aim, the Decipher also gives us a whole transcriptomic profile, what’s called the grid. And there’s very limited data about the whole transcriptomic profile in patients that were reclassified versus the NCCN classification. So we wanted to see what’s the difference in the grid between NTP53 activity between those that were up-classified versus staying in the same risk.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
